Table 1.
Variablea | Low Antibody Group | High Antibody Group | Low IFN-γ Elispot Group | High IFN-γ Elispot Group | All |
---|---|---|---|---|---|
Neutralizing antibody, ID50 | 54 (37–76) | 305 (243–408) | 132 (42–305) | 134 (60–302) | 134 (54–302) |
Elispot CD8+ IFN-γ, spots/5 × 105 cells | 8 (−2 to 30) | 15 (−1 to 45) | 1 (−8 to 8) | 35 (13–59) | 10 (−2 to 39) |
Elispot total IFN-γ, spots/2 × 105 cells | 44 (6–125) | 66 (13–141) | 9 (−13 to 16) | 138 (97–176) | 60 (9–138) |
IFN-α, pg/mL | 54 (19–103) | 63 (11–119) | 38 (6–92) | 84 (25–140) | 56 (16–110) |
IFN-β, pg/mL | 2 (−6 to 6) | 0 (−6 to 5) | 0 (−7 to 5) | 1 (−5 to 6) | 1 (−6 to 5) |
IFN-γ, pg/mL | 117 (−30 to 1312) | 341 (41–1495) | 90 (−73 to 646) | 598 (78–1811) | 271 (0–1312) |
IL-10, pg/mL | 3 (−1 to 11) | 3 (0–10) | 3 (0–7) | 3 (−1 to 15) | 3 (−1 to 10) |
IL-12p40, pg/mL | 61 (25–118) | 62 (30–125) | 43 (21–99) | 76 (31–126) | 61 (27–119) |
IL-12p70, pg/mL | 2 (1–5) | 4 (1–6) | 2 (1–4) | 4 (1–6) | 3 (1–5) |
IL-18, pg/mL | 1 (−2 to 4) | 1 (−2 to 4) | 1 (−3 to 3) | 1 (−2 to 4) | 1 (−2 to 4) |
IL-1β, pg/mL | 54 (23–126) | 46 (23–98) | 41 (23–85) | 58 (25–147) | 50 (23–113) |
IL-2, pg/mL | 15 (4–35) | 21 (5–42) | 7 (0–27) | 24 (10–43) | 18 (4–39) |
IL-4, pg/mL | 0 (−4 to 4) | 1 (−3 to 4) | 0 (−4 to 3) | 1 (−1 to 5) | 1 (−3 to 4) |
IL-6, pg/mL | 1010 (623–1945) | 926 (517–1553) | 805 (442–1285) | 1163 (652–1924) | 977 (580–1836) |
TNF-α, pg/mL | 169 (97–279) | 134 (70–310) | 132 (63–213) | 197 (101–374) | 149 (89–288) |
aData are median values (interquartile ranges). Elispot response and secreted cytokine response is defined as the subject-specific median vaccinia virus–stimulated response (measured in triplicates) minus the median unstimulated response (also measured in triplicates). Negative values indicate that stimulated values were on average smaller than unstimulated values.
Abbreviations: ID50, titer that inhibits 50% of virus activity; IFN, interferon; IL, interleukin; TNF, tumor necrosis factor.